Details

Autor(en) / Beteiligte

• O’Rorke, Michael
• Chrischilles, Elizabeth
• Chamberlain, Alanna M.
• Chrischilles, Elizabeth A.
• Cowell, Lindsay G.
• Dillon, Joseph S.
• Early, Carol
• Else, Tobias
• Gamblin, T. Clark
• Geller, David
• Gellerman, Elyse
• Gryzlak, Brian
• Halfdanarson, Thorvardur R.
• Hamilton, Harley C.
• He, Fiona C.
• Hourcade, Juan Pablo
• Indrees, Kamran
• Kazmi, Syed M.
• Lancaster, William
• Lewis‐Hughes, Amoni
• Liu, Mei
• Mailman, Josh A.
• McDowell, Bradley
• Ramirez, Robert A.
• Ramnaraign, Brian H.
• Sanoff, Hanna K.
• Soares, Heloisa P.
• Sukrithan, Vineeth
• Taylor, Bradley W.
• Tepper, Mia S.
• Wahmann, Maryann
• Zamba, Gideon K. D.

Titel

Making progress against rare cancers: A case study on neuroendocrine tumors

Ist Teil von

• Cancer, 2024-05, Vol.130 (9), p.1568-1574

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In April 2023, the National Cancer Institute offered a roadmap for cancer research to achieve Cancer Moonshot goals. To reach these goals requires making progress for all cancers, not just those that are most common. Achieving progress against rare cancers, as well as common cancers, requires involvement of large clinical research networks. In 2020, the Patient‐Centered Outcomes Research Institute (PCORI) launched an initiative on Conducting Rare Disease Research using PCORnet, the National Patient‐Centered Clinical Research Network. The purpose of this commentary is to introduce the broader community of cancer researchers to the PCORnet NET‐PRO study (comparing the effects of different treatment approaches for neuroendocrine tumors on patient‐reported outcomes) thereby demonstrating how researchers can use the PCORnet infrastructure to conduct large‐scale patient‐centered studies of rare cancers. Achieving progress against rare cancers requires involvement of large clinical research networks. This commentary showcases the NET‐PRO study (comparing the effects of different treatment approaches for neuroendocrine tumors on patient‐reported outcomes) to demonstrate how cancer researchers can conduct large‐scale patient‐centered studies of rare cancers using PCORnet.